The JNK Inhibitor XG-102 Protects against TNBS-Induced Colitis

• Kirstin Reinecke,

  Affiliation Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

  ⨯
• Sevgi Eminel,

  Affiliation Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

  ⨯
• Franziska Dierck,

  Affiliation Pharmaceutical Institute, University of Kiel, Kiel, Germany

  ⨯
• Wibke Roessner,

  Affiliation Pharmaceutical Institute, University of Kiel, Kiel, Germany

  ⨯
• Sabine Kersting,

  Affiliation Department of Visceral and General Surgery, St. Josef Hospital, Ruhr-University Bochum, Bochum, Germany

  ⨯
• Ansgar Michael Chromik,

  Affiliation Department of Visceral and General Surgery, St. Josef Hospital, Ruhr-University Bochum, Bochum, Germany

  ⨯
• Olga Gavrilova,

  Affiliation Institute for Clinical Molecular Biology, University of Kiel, University Hospital Schleswig-Holstein, Kiel, Campus Kiel, Kiel, Germany

  ⨯
• Ale Laukevicience,

  Affiliation Department of Physiology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania

  ⨯
• Ivo Leuschner,

  Affiliation Institute of Pathology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

  ⨯
• Vicki Waetzig,

  Affiliation Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

  ⨯
• Philip Rosenstiel,

  Affiliation Institute for Clinical Molecular Biology, University of Kiel, University Hospital Schleswig-Holstein, Kiel, Campus Kiel, Kiel, Germany

  ⨯
• Thomas Herdegen ,

  * E-mail: herdegen.office@pharmakologie.uni-kiel.de

  Affiliation Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

  ⨯
• Christian Sina

  Affiliation Institute for Clinical Molecular Biology, University of Kiel, University Hospital Schleswig-Holstein, Kiel, Campus Kiel, Kiel, Germany

  ⨯